FLT3 and acute myeloid leukemia: The Children’s Oncology Group (COG) incorporated sorafenib and, more recently, gilteritinib into pediatric regimens (e.g., AAML1031, NCT03730012, and NCT05066718), demonstrating biological activity and manageable toxicity profiles in relapsed or refractory FLT3-mutated AML [87,88].